邮件订阅 RSS
任新瑜, 袁礼, 沈松杰, 吴焕文, 陆俊良, 梁智勇. 联合检测CK5/6、CK14和表皮生长因子受体对基底样三阴乳腺癌的诊断价值[J]. 协和医学杂志, 2017, 8(2-3): 154-160. DOI: 10.3969/j.issn.1674-9081.2017.03.013
引用本文: 任新瑜, 袁礼, 沈松杰, 吴焕文, 陆俊良, 梁智勇. 联合检测CK5/6、CK14和表皮生长因子受体对基底样三阴乳腺癌的诊断价值[J]. 协和医学杂志, 2017, 8(2-3): 154-160. DOI: 10.3969/j.issn.1674-9081.2017.03.013
shu
Xin-yu REN, Li YUAN, Song-jie SHEN, Huan-wen WU, Jun-liang LU, Zhi-yong LIANG. Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 154-160. DOI: 10.3969/j.issn.1674-9081.2017.03.013
Citation: Xin-yu REN, Li YUAN, Song-jie SHEN, Huan-wen WU, Jun-liang LU, Zhi-yong LIANG. Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(2-3): 154-160. DOI: 10.3969/j.issn.1674-9081.2017.03.013
shu

联合检测CK5/6、CK14和表皮生长因子受体对基底样三阴乳腺癌的诊断价值

Combined Detection of CK5/6, CK14 and EGFR in Diagnosis of Basal-like Subtype Triple Negative Breast Cancer

    摘要
  • 摘要:
        目的        探讨联合检测CK5/6、CK14和表皮生长因子受体(epidermal growth factor receptor, EGFR)对基底样三阴乳腺癌的诊断价值。
        方法      北京协和医院2000年1月至2011年12月经组织病理学证实的115例三阴乳腺癌患者, 收集其临床及病理资料。应用免疫组织化学法检测所有石蜡标本中CK5/6, CK14和EGFR的表达, 以此判定是否为基底样三阴乳腺癌。以三者联合检测结果作为金标准, 计算CK5/6, CK14和EGFR单独检测、两两联合检测的敏感性和特异性。进一步分析基底样三阴乳腺癌和非基底样三阴乳腺癌在年龄、肿瘤大小、组织学类型等临床及病理特征方面的差异。
        结果      115例三阴乳腺癌患者平均患病年龄为(50.7±13.6)岁。免疫组织化学结果显示, 单独检测CK5/6, 基底样三阴乳腺癌阳性率为29.6%(34/115), CK14为21.7%(18/83), EGFR为60.9%(70/115)。CK14, CK5/6和EGFR三者联合检测阳性率为67.8%(78/115)。将三者联合检测的阳性例数作为金标准, 则EGFR与CK5/6联合检测敏感性及特异性分别可达98.7%及100%。基底样三阴乳腺癌与非基底样三阴乳腺癌在组织学类型、分级, 淋巴结转移情况, 死亡率方面差异有统计学意义(P均 < 0.05), 基底样三阴乳腺癌总生存期显著缩短(HR=0.363, 95% CI:0.139~0.947)。
        结论      CK14、CK5/6和EGFR联合检测能够标识出最多数量的基底样三阴乳腺癌。基底样三阴乳腺癌预后比非基底样三阴乳腺癌预后更差, 病理识别很重要。

     

    Abstract:
        Objective       To investigate the value of combined detection of CK5/6, CK14 and epidermal growth factor receptor (EGFR) in diagnosing basal-like subtype triple negative breast cancer (TNBC).
        Methods       The clinical and pathological data of 115 patients diagnosed with TNBC were recorded from January 2000 to December 2011. The expression of CK5/6, CK14 and EGFR were detected with immunohistochemical methods using paraffin specimens. Combined detection result of the three markers was used as gold standard, then the sensitivity and specificity of CK5/6, CK14 and EGFR were detected by single marker and two combined assays.The differences between basal-like and non basal-like subtype TNBC in age, tumor size, tumor histological type and other clinicopathological issues were compared.
        Results       The mean age of 115 patients with TNBC was (50.7±13.6) years. Immunhistochemical result showed that single marker positivity was 29.6% (34/115), 21.7% (18/83), and 60.9% (70/115) for CK5/6, CK14, and EGFR, respectively. Combined detection of the three markers, the positive rate was 67.8% (78/115). Taking three markers combination as a golden standard, the sensitivity and specificity of EGFR and CK5/6 combination were 98.7% and 100%. There were significant differences between basal-like and non basal-like subtype TNBC in histological type, tumor grade, lymph node metastasis and mortality(all P < 0.05). Survival analysis showed that the overall survival period of basal-like subtype TNBC was significant shortened(HR=0.363, 95% CI:0.139~0.947).
        Conclusions       Combined detection of CK5/6, CK14 and EGFR could identifiy the largest number of basal-like subtype TNBC. The prognosis of basal-like subtype TNBC is worse than that of non basal-like subtype TNBC, and it is important to identify the subtype.

     

    • HTML全文
    • 参考文献(22)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回